Perrigo (PRGO) Net Cash Flow Growth (1y) (2014 - 2026)
Perrigo (PRGO) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -1,020.00% |
| 10 | Perrigo | 1.43 Bn | 1.07 Bn | 325.50 Mn | -12.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -12.70% |
| Dec 31, 2025 | 110.98% |
| Sep 27, 2025 | -102.20% |
| Jun 28, 2025 | 115.93% |
| Mar 29, 2025 | -78.19% |
| Dec 31, 2024 | -721.80% |
| Sep 28, 2024 | 1,698.42% |
| Jun 29, 2024 | -113,500.00% |
| Mar 30, 2024 | -67.58% |
| Dec 31, 2023 | 20.36% |
| Sep 30, 2023 | 1,174.47% |
| Jul 1, 2023 | 99.99% |
| Apr 1, 2023 | -156.62% |
| Dec 31, 2022 | 157.18% |
| Oct 1, 2022 | -100.27% |
| Jul 2, 2022 | -886.43% |
| Apr 2, 2022 | 157.22% |
| Dec 31, 2021 | 6.04% |
| Oct 2, 2021 | 383.12% |
| Jul 3, 2021 | -115.35% |